Literature DB >> 29210321

Lessons for reviewing clinical trials using induced pluripotent stem cells: examining the case of a first-in-human trial for age-related macular degeneration.

Kayo Takashima1, Yusuke Inoue1, Shimon Tashiro2, Kaori Muto1.   

Abstract

Entities:  

Keywords:  AMD; age-related macular degeneration; committee meeting minutes; direct benefit; first-in-human trial; iPSC; induced pluripotent stem cell; protecting research participants; reasonable accommodation; review committee; risk assessment; subject selection

Mesh：

Year:  2017        PMID： 29210321     DOI： 10.2217/rme-2017-0130

Source DB:  PubMed          Journal:  Regen Med        ISSN： 1746-0751            Impact factor:   3.806


× No keyword cloud information.
  4 in total

Review 1.  Gene Editing in Human Pluripotent Stem Cells: Recent Advances for Clinical Therapies.

Authors:  Hatice Burcu Şişli; Taha Bartu Hayal; Selin Seçkin; Selinay Şenkal; Binnur Kıratlı; Fikrettin Şahin; Ayşegül Doğan
Journal:  Adv Exp Med Biol       Date:  2020       Impact factor: 2.622

2.  Why Do Muse Stem Cells Present an Enduring Stress Capacity? Hints from a Comparative Proteome Analysis.

Authors:  Mustafa B Acar; Domenico Aprile; Serife Ayaz-Guner; Huseyin Guner; Coskun Tez; Giovanni Di Bernardo; Gianfranco Peluso; Servet Ozcan; Umberto Galderisi
Journal:  Int J Mol Sci       Date:  2021-02-19       Impact factor: 5.923

Review 3.  Reflection on the enactment and impact of safety laws for regenerative medicine in Japan.

Authors:  Kayo Takashima; Michael Morrison; Jusaku Minari
Journal:  Stem Cell Reports       Date:  2021-05-20       Impact factor: 7.765

Review 4.  Clinical-Grade Human Pluripotent Stem Cells for Cell Therapy: Characterization Strategy.

Authors:  Daniela Rehakova; Tereza Souralova; Irena Koutna
Journal:  Int J Mol Sci       Date:  2020-03-31       Impact factor: 5.923
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.